Non-GCB tumors predicted worse PFS ( hazard ratio [ HR ] , 3.21 ; 95 % CI , 1.29 to 8.00 ; P = .01 ) and OS ( HR , 6.09 ; 95 % CI , 1.37 to 27.03 ; P = .02 ) among patients treated with R-CHOP compared with patients who received R-ACVBP , whereas there were no significant survival differences between these regimens among patients with GCB tumors .